Tevogen TVGN

NASDAQ TVGN
$5.33 -0.39 (-6.82%)
At close: Nov 13, 2026 · 4:00 PM EST

Tevogen (TVGN) stock price is $5.33, down 6.82% on the day, as of Nov 13, 2026. It has a market cap of $22.68Mn, and is classified in the Gene and Cell Therapy industry (Healthcare sector).

Key Stats
Market Cap22.68 Mn
P/E-0.92
FCF (Yr)-12.39 Mn
ROA (Yr)-666.45
EV to EBIT-0.90
Net Income (Yr)-26.83 Mn
Enterprise Value19.32 Mn
Add ratio to table…

About

Tevogen Bio Holdings Inc. is a clinical stage specialty immunotherapy company that develops off the shelf precision T cell therapies using its ExacTcell technology. The company focuses on infectious diseases, cancers and other disorders with the goal of addressing unmet medical needs. Its lead product candidate, TGVN 489, is an allogeneic CD8 positive T cell therapy designed for COVID 19 patients and long COVID conditions. Tevogen Bio Holdings Inc. aims to deliver therapies…

Read more ↓
Sector: Healthcare Sector rationale Tevogen Bio Holdings is a clinical-stage immunotherapy company developing T cell therapies for infectious diseases and cancers, such as TGVN 489 for COVID-19. Its business model is centered on the discovery and development of medical products (biotechnology/pharmaceuticals) to be sold to hospitals and clinics. Industry: Gene and Cell Therapy Gene and Cell Therapy Primary Tevogen Bio Holdings develops allogeneic T cell therapies, such as TGVN 489 and TGVN 920, which are engineered cell therapies designed to modify or replace immune cells. The company's core ExacTcell platform focuses on the selection and expansion of CD8 positive T cells for treating infectious diseases and cancers. Classified using BQ-MICS CIK: 0001860871
Peer percentiles

How Tevogen ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 14, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −0.92xMedian 17.0x 25th
  • P/FCFNegative free cash flow −1.96xMedian 19.0x 32nd
  • P/Operating cash flowNegative operating cash flow −1.96xMedian 16.4x 32nd
  • P/SRevenue is not positive −75.0xMedian 8.38x Not meaningful —
  • P/BNegative shareholder equity −2.55xMedian 2.04x Not meaningful —
  • P/Tangible bookNegative tangible equity −2.55xMedian 2.31x Not meaningful —
  • EV/EBITDANegative EBITDA −1.40xMedian 14.6x 29th
  • EV/EBITNegative EBIT −1.39xMedian 18.4x 31st
  • EV/RevenueRevenue is not positive −98.0xMedian 6.34x Not meaningful —
  • EV/FCFNegative free cash flow −2.56xMedian 23.4x 33rd
  • EV/Operating cash flowNegative operating cash flow −2.56xMedian 19.3x 33rd
  • PEG (3Y EPS CAGR)Negative earnings 0.01Median 0.43 Not meaningful —
Peer group

Peer Comparison

Companies in the Gene and Cell Therapy
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 LLY ELI LILLY & Co 1,359.75 Bn46.7415.7349.50 Bn
2 JNJ Johnson & Johnson 688.76 Bn42.836.9344.65 Bn
3 ABBV AbbVie Inc. 521.69 Bn50.487.9080.90 Bn
4 MRK Merck & Co., Inc. 364.31 Bn148.685.4153.78 Bn
5 NVS Novartis Ag 306.35 Bn17.915.08-
6 AZN Astrazeneca Plc 285.96 Bn25.924.82-6.68 Bn
7 AMGN Amgen Inc 251.88 Bn26.836.4754.01 Bn
8 TVGN Tevogen Inc. 0.02 Bn-0.92-74.960.01 Bn